C33G3.4 Antibody
Description
C33 Antigen in Virology
The search results reference a C33 antigen associated with human T-cell leukemia virus type 1 (HTLV-1):
-
C33 is a glycoprotein recognized by monoclonal antibodies (e.g., M104, C33) that inhibit HTLV-1-induced syncytium formation .
-
Molecular characterization shows it is a type III transmembrane protein (29.6 kDa) with N-linked glycosylation sites .
-
Expressed in CD4+ T cells, B cells, monocytes, and granulocytes, its glycosylation patterns differ between HTLV-1-negative and -positive cells .
C33 in Antibody Engineering
Another "C33" context involves antibody humanization:
-
A study humanized murine IgG3 anti-GD2 antibody m3F8, improving antibody-dependent cell-mediated cytotoxicity (ADCC). While not directly related to "C33G3.4," this demonstrates methodologies for modifying antibodies to enhance therapeutic efficacy .
Gaps and Limitations
-
Nomenclature ambiguity: The term "C33G3.4" does not align with established antibody naming conventions (e.g., WHO’s INN system) or glycoprotein identifiers in virology.
-
Database absence: No matches were found in antibody databases (e.g., AntibodyRegistry, CiteAb) or genomic repositories (e.g., UniProt, NCBI).
Recommendations for Further Research
| Step | Action | Purpose |
|---|---|---|
| 1 | Verify nomenclature | Confirm if "C33G3.4" refers to a gene locus (e.g., C. elegans gene C33G3.4) or a proprietary antibody. |
| 2 | Explore patent databases | Search USPTO or WIPO for unpublished/commercial antibodies. |
| 3 | Contact manufacturers | Query companies like Abcam or Thermo Fisher Scientific for proprietary reagents. |
Key Research Antibody Trends (2022–2032)
The global research antibodies market (valued at $10.38B in 2022) emphasizes:
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
